Subtype
Renal Cell Carcinoma
CI-CAN-00006578RCCExplore in graph →
376 active trials17 approved drugs60 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006578RCCExplore in graph →
Clinical trials
1,622 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (276)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00617253 | Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients | completed | Phase 2 | 9 | Novo Nordisk A/SINDUSTRY | 2 | Mar 1, 2017 | clinicaltrials |
| NCT02607553 | Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA | completed | Phase 2 | 2 | GenSpera, Inc.INDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT02677337 |
| NCCN Renal Cell Registry |
| completed |
| N/A |
| 120 |
| Duke UniversityOTHER |
| 1 |
| Feb 17, 2017 |
| clinicaltrials |
| NCT00423332 | Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma | completed | Phase 2 | 105 | AstraZenecaINDUSTRY | 2 | Feb 2, 2017 | clinicaltrials |
| NCT02143492 | Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC | completed | — | 11 | Argos TherapeuticsINDUSTRY | 1 | Jan 24, 2017 | clinicaltrials |
| NCT00256880 | Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma | completed | Phase 2 | 100 | GlaxoSmithKlineINDUSTRY | 2 | Jan 18, 2017 | clinicaltrials |
| NCT02334709 | Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect. | completed | Phase 1 / Phase 2 | 13 | University Hospital, GhentOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 | clinicaltrials |
| NCT00172003 | Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis | completed | Phase 4 | 50 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2016 | clinicaltrials |
| NCT00903175 | Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma(RECORD-3) | completed | Phase 2 | 471 | Novartis PharmaceuticalsINDUSTRY | 19 | Nov 8, 2016 | clinicaltrials |
| NCT01392729 | An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA) | completed | — | 40 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01585974 | Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma(TURCOS) | completed | — | 151 | BayerINDUSTRY | 1 | Oct 19, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01283048 | Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 1 | 32 | Toni Choueiri, MDOTHER | 1 | Sep 21, 2016 | clinicaltrials |
| NCT00126594 | Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2016 | clinicaltrials |
| NCT02627144 | Bevacizumab in Metastatic Renal Cancer | completed | — | 365 | Hoffmann-La RocheINDUSTRY | 1 | Aug 29, 2016 | clinicaltrials |
| NCT01442090 | Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy | completed | Phase 2 | 85 | Genentech, Inc.INDUSTRY | 5 | Aug 10, 2016 | clinicaltrials |
| NCT01404104 | Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma | completed | N/A | 11 | St. Joseph's Healthcare HamiltonOTHER | 1 | Jul 27, 2016 | clinicaltrials |
| NCT00738530 | A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy | completed | Phase 3 | 649 | Hoffmann-La RocheINDUSTRY | 18 | Jun 23, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT00465179 | Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer | completed | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 7, 2016 | clinicaltrials |
| NCT01491672 | Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma(RECORD-4) | completed | Phase 2 | 134 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 6, 2016 | clinicaltrials |
| NCT01202032 | Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors(PARASOL) | completed | Phase 1 | 36 | Centre Leon BerardOTHER | 1 | May 18, 2016 | clinicaltrials |
| NCT00631371 | Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects(INTORACT) | completed | Phase 3 | 791 | PfizerINDUSTRY | 30 | Apr 27, 2016 | clinicaltrials |
| NCT01367457 | INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus | completed | — | 243 | PfizerINDUSTRY | 1 | Apr 27, 2016 | clinicaltrials |
| NCT00556049 | Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 72 | Massachusetts General HospitalOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT01497821 | AMG 172 First in Human Study in Patients With Kidney Cancer | completed | Phase 1 | 37 | AmgenINDUSTRY | 3 | Mar 25, 2016 | clinicaltrials |
| NCT00467025 | AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib | completed | Phase 2 | 152 | AmgenINDUSTRY | 0 | Mar 23, 2016 | clinicaltrials |
| NCT00445042 | Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer | completed | Phase 2 | 71 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00445523 | Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer | completed | Phase 2 | 28 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00446368 | Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer(RAD001) | completed | Phase 2 | 66 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00448149 | Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer | completed | Phase 1 / Phase 2 | 55 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01062178 | Efficacy of Ultrasound Contrast Agent to Assess Renal Masses | completed | Phase 2 | 167 | University Health Network, TorontoOTHER | 1 | Mar 8, 2016 | clinicaltrials |
| NCT02370290 | Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer | completed | — | 74 | University of Southern CaliforniaOTHER | 1 | Mar 3, 2016 | clinicaltrials |
| NCT00227760 | Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Feb 29, 2016 | clinicaltrials |
| NCT01014065 | A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect)(SUPER) | completed | — | 42 | AHS Cancer Control AlbertaOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT00334282 | Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma | completed | Phase 3 | 435 | GlaxoSmithKlineINDUSTRY | 25 | Feb 5, 2016 | clinicaltrials |
| NCT01402089 | Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients | completed | Phase 4 | 54 | Markus JoergerOTHER | 1 | Feb 2, 2016 | clinicaltrials |
| NCT00324870 | Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2016 | clinicaltrials |
| NCT01390519 | A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor(OSAT) | completed | — | 30 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 13, 2016 | clinicaltrials |
| NCT00531544 | A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248 | completed | N/A | 350 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Jan 5, 2016 | clinicaltrials |
| NCT00618982 | Sorafenib Dose Escalation in Renal Cell Carcinoma | completed | Phase 2 | 83 | BayerINDUSTRY | 5 | Dec 24, 2015 | clinicaltrials |
| NCT00480389 | Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal | completed | Phase 2 | 19 | University Health Network, TorontoOTHER | 1 | Dec 9, 2015 | clinicaltrials |
| NCT01223027 | Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 3 | 564 | Novartis PharmaceuticalsINDUSTRY | 27 | Dec 7, 2015 | clinicaltrials |
| NCT00625456 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | completed | Phase 1 | 23 | Jennerex BiotherapeuticsINDUSTRY | 2 | Dec 3, 2015 | clinicaltrials |
| NCT00694096 | Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response | completed | Phase 1 | 25 | University of UtahOTHER | 1 | Dec 1, 2015 | clinicaltrials |
| NCT01122615 | Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) | completed | Phase 1 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT01227213 | The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma | completed | — | 20 | Radboud University Medical CenterOTHER | 1 | Oct 30, 2015 | clinicaltrials |
| NCT01525017 | A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer | completed | Phase 1 | 12 | MendusINDUSTRY | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00842790 | Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging(REMISCAN) | completed | — | 107 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 6, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Mar 1, 2017source: clinicaltrials